ArticleScientific reports2025
Polydopamine-coated double emulsion capsules for on-demand drug release with reduced passive leakage.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Synthesis,ACS omega · 2026Article
- Liposomal encapsulation of a synthetic bromophenol for antitumor efficacy and apoptotic activity in cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Double emulsions (DEs) are widely explored in pharmaceuticals due to their ability to encapsulate both hydrophilic and hydrophobic drugs. However, their inherent instability limits their effectiveness in controlled drug delivery. Double emulsion capsules (DECs), formed by encapsulating DEs within a polymer shell, improve structural stability but still suffer from unintended drug diffusion due to the porous nature of polymeric shells. Polydopamine (PDA), a bioinspired polymer known for its strong adhesion, biocompatibility, and chemical stability, is a promising coating material for biomedical applications. However, research on its coating on DECs and its potential impact on passive leakage remains underexplored. Here we report PDA-coated DECs as an on-demand drug release system. The PDA coating effectively reduces passive leakage by forming an additional PDA layer on the DEC surface. Under optimized coating conditions, the passive leakage of coated DECs is ~ 20% lower than that of uncoated DECs for 8 days. Also, on-demand drug release is demonstrated through the photothermal effect of PDA, which enables localized heating under NIR laser irradiation. This study highlights PDA-coated DECs as a versatile drug delivery platform with enhanced stability, tunable release properties, and photothermal activation, making them promising for targeted drug delivery, implantable therapeutics, and precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.